Mahmoud Omidi

Dr. Mahmoud Omidi

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2024 in Marine Pollution Bulletin
Verified
Journal Article
Closed access
MTMahmoud Taghavi
Mahmoud Taghavi
ASAmir Shadboorestan
Amir Shadboorestan
LKLaleh R. Kalankesh
Laleh R. Kalankesh
AMAfshin Mohammadi-Bardbori
Afshin Mohammadi-Bardbori
HGHamid Reza Ghaffari
Hamid Reza Ghaffari
MOMahmoud Omidi
Mahmoud Omidi

1 September 2015 in European Journal of Pharmacology
Verified
Journal Article
Closed access
ABAfshin Mohammadi Bardbori
Afshin Mohammadi Bardbori
ANAsma Najibi
Asma Najibi
NANajmeh Amirzadegan
Najmeh Amirzadegan
RGRaziyeh Gharibi
Raziyeh Gharibi
ADAyat Dashti
Ayat Dashti
HNHossein Niknahad
Hossein Niknahad

26 October 2020 in Trials
Verified
Journal Article
Open access
PDF file
AZAva Ziaei
Ava Ziaei
PDParivash Davoodian
Parivash Davoodian
HDHabib Dadvand
Habib Dadvand
OSOmid Safa
Omid Safa
SHSoheil Hassanipour
Soheil Hassanipour
MFMohammad Fathalipour
Mohammad Fathalipour
Objectives: We will evaluate the efficacy and safety of Melatonin, compared to the standard therapeutic regimen on clinical symptoms and serum inflammatory parameters in patients with confirmed COVID-19, who are moderately ill. Trial design: This is a single-center, randomized, double-blind, placebo-controlled clinical trial with a parallel-group design conducted at Shahid Mohammadi Hospital, Bandar Abbas, Iran. Participants: All patients admitted to Severe Acute Respiratory Syndrome Departments of Shahid Mohammadi Hospital, Bandar Abbas, Iran will be screened for the following criteria. Inclusion criteria: 1. Age ≥20 years 2. Confirmed SARS-CoV-2 diagnosis (positive polymerase chain reaction). 3. Moderate COVID-19 pneumonia (via computed tomography and or X-ray imaging), requiring hospitalization. 4. Hospitalized ≤48 hours. 5. Signing informed consent and willingness of the participant to accept randomization to any assigned treatment arm. Exclusion criteria: 1. Underlying diseases, including chronic hypertension, diabetes mellitus, seizure, depression, chronic hepatitis, cirrhosis, and cholestatic liver diseases. 2. Severe and critical COVID-19 pneumonia. 3. Use of warfarin, corticosteroids, hormonal drugs, alcohol, other antiviral and investigational medicines, and illegal drugs (during the last 30 days). 4. History of known allergy to Melatonin. 5. Pregnancy and breastfeeding. Intervention and comparator: Intervention group: The standard treatment regimen for COVID-19, according to the Iranian Ministry of Health and Medical Education's protocol, along with Melatonin capsules at a dose of 50 mg daily for a period of seven days. Control group: The standard therapeutic regimen for COVID-19 along with Melatonin-like placebo capsules at a dose of one capsule daily for a period of seven days. Both Melatonin and placebo capsules were prepared at the Faculty of Pharmacy and Pharmaceutical Sciences, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Main outcomes: The primary outcomes are the recovery rate of clinical symptoms and oxygen saturation as well as improvement of serum inflammatory parameters, including C-reactive protein, tumor necrosis factor-alpha (TNF-ɑ), interleukin-1β (IL-1β), and IL-6 within seven days of randomization. The secondary outcomes are the time to improve clinical and paraclinical features along with the incidence of serious adverse drug reactions within seven days of randomization. Randomization: Included patients will be allocated to one of the study arms using block randomization in a 1:1 ratio (each block consists of 10 patients). This randomization method ensures a balanced allocation between the arms during the study. A web-based system will generate random numbers for the allocation sequence and concealment of participants. Each number relates to one of the study arms. Blinding (masking): All study participants, clinicians, nurses, research coordinators, and those analyzing the data are blinded to the group assignment. Numbers to be randomized (sample size): A total of 60 patients randomized into two groups (30 in each group). Trial Status: The trial protocol is Version 1.0, August 14, 2020. Recruitment began August 22, 2020, and is anticipated to be completed by November 30, 2020. Trial registration: The trial protocol has been registered in the Iranian Registry of Clinical Trials (IRCT). The registration number is “IRCT20200506047323N5”. The registration date was 14 August 2020. Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.


18 December 2015 in Xenobiotica
Verified
Journal Article
Closed access
PDF file
ASArastoo Saeedi
Arastoo Saeedi
MOMahmoud Omidi
Mahmoud Omidi
MKMohammad Javad Khoahnoud
Mohammad Javad Khoahnoud
ABAfshin Mohammadi Bardbori
Afshin Mohammadi Bardbori
1. Methyl tert-butyl ether (MTBE) is commonly used as an octane booster and oxygenate additive to gasoline. The assumed toxic effects of MTBE on human health are a matter of great debate. Exposure to MTBE has been shown to induce oxidative damage and no mechanistic explanation is available so far. Our goals were to determine whether MTBE is a mitochondrial toxicant, if so, what mechanism(s) is involved. 2. Male Sprague-Dawley rats were received MTBE in drinking water for 3 months. At the end of treatments, animals were killed, liver and blood samples were collected for biochemical and histopathological studies, and oxidative stress biomarkers. The rat liver mitochondria were isolated and several mitochondrial indices were measured. 3. We found that zinc plasma levels were remarkably declined with MTBE and N, N, N′, N′-Tetrakis (2-pyridylmethyl) ethylenediamine (TPEN; a zinc chelator) exposure. MTBE induced oxidative damage and caused mitochondrial dysfunctions in rats. Supplementation with zinc was able to protect against MTBE-induced cellular and sub-cellular toxicity. 4. Our results demonstrated that long-term exposure to MTBE is associated with zinc deficiency, oxidative stress, and mitochondrial energy failure in rat.

30 September 2023 in Cell and Tissue Banking
Verified
Journal Article
Closed access
PDF file
ESEnsieh Salehi
Ensieh Salehi
ASAmir Shadboorestan
Amir Shadboorestan
AMAfshin Mohammadi-Bardbori
Afshin Mohammadi-Bardbori
AMAbedeh Mousavi
Abedeh Mousavi
EKElias Kargar-Abargouei
Elias Kargar-Abargouei
MOMahmoud Omidi
Mahmoud Omidi